APA (7th ed.) Citation

AH, K., KP, K., JT, S., CD, L., J, L., EM, O., . . . DY, O. (2023). Atezolizumab Plus PEGPH20 Versus Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma and Gastric Cancer: MORPHEUS Phase Ib/II Umbrella Randomized Study Platform. The oncologist, 28(6), 553. https://doi.org/10.1093/oncolo/oyad022

Chicago Style (17th ed.) Citation

AH, Ko, et al. "Atezolizumab Plus PEGPH20 Versus Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma and Gastric Cancer: MORPHEUS Phase Ib/II Umbrella Randomized Study Platform." The Oncologist 28, no. 6 (2023): 553. https://doi.org/10.1093/oncolo/oyad022.

MLA (9th ed.) Citation

AH, Ko, et al. "Atezolizumab Plus PEGPH20 Versus Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma and Gastric Cancer: MORPHEUS Phase Ib/II Umbrella Randomized Study Platform." The Oncologist, vol. 28, no. 6, 2023, p. 553, https://doi.org/10.1093/oncolo/oyad022.